NJ Bio Moves Headquarters to Princeton, New Jersey

New Headquarters for NJ Bio at 350 Carter Road, Princeton, NJ

PRINCETON, N.J.--(BUSINESS WIRE)--May 4, 2021--

NJ Biopharmaceuticals LLC (d/b/a NJ Bio), an expert provider of chemistry and biopharmaceutical services specializing in bioconjugation, custom synthesis, flow chemistry, and process development, announced the move of its headquarters from North Brunswick to Princeton, New Jersey.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210504005811/en/

New Headquarters for NJ Bio at 350 Carter Road, Princeton, NJ (Photo: Business Wire)

The 35,000-square-foot, state-of-the-art laboratory space will be located at 350 Carter Road, at a site formerly occupied by Bristol Myers Squibb. Over time, the company plans to expand further within the same location. Current staff will move from North Brunswick to Princeton, and the facility will be fully operational by July 1, 2021. NJ Bio will continue to operate its facility in Bristol, PA, with plans for future growth at that site, including GMP manufacturing capabilities for small molecules as well as bioconjugation.

“On behalf of the board of directors and senior management at NJ Bio, I am excited to announce this move,” said Nareshkumar Jain, Ph.D., President and CEO of NJ Bio. “Our expansion to this advanced facility demonstrates the rapid growth of NJ Bio in just over two years. This new location, well-equipped with the latest instruments, and staffed by exceptional scientists, will ensure that NJ Bio continues to remain an outstanding partner to our clients, delivering high value and results for their most challenging research and development needs.”

About NJ Bio

NJ Bio is an integrated chemistry service provider with expertise in bioconjugation, payload-linker synthesis, nucleotide chemistry, and application of BioNMR to drug discovery programs, including protein degraders. NJ Bio also offers expertise in flow chemistry and process development and provides innovative solutions for large-scale continuous manufacturing needs. NJ Bio’s clients range from large pharmaceutical and biotechnology companies to start-ups.

For additional information, visit www.njbio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210504005811/en/

CONTACT: Media Contact

Reva Raghupathi, PhD, MBA

Vice-President, Strategic Alliances, NJ Bio

Email:info@njbio.com

KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY

INDUSTRY KEYWORD: RESEARCH BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE ONCOLOGY

SOURCE: NJ Biopharmaceuticals LLC

Copyright Business Wire 2021.

PUB: 05/04/2021 12:03 PM/DISC: 05/04/2021 12:03 PM

http://www.businesswire.com/news/home/20210504005811/en

Copyright Business Wire 2021.

DISCLAIMER FOR COMMENTS: The views expressed by public comments are not those of this company or its affiliated companies. Please note by clicking on "Post" you acknowledge that you have read the TERMS OF USE and the comment you are posting is in compliance with such terms. Your comments may be used on air. Be polite. Inappropriate posts or posts containing offsite links, images, GIFs, inappropriate language, or memes may be removed by the moderator. Job listings and similar posts are likely automated SPAM messages from Facebook and are not placed by WFMZ-TV.